Skip to main content
S. 483 119th Congress Senate

Responsibility in Drug Advertising Act of 2025

Official title: A bill to amend the Federal Food, Drug, and Cosmetic Act to restrict direct-to-consumer drug advertising.

Introduced: February 6, 2025 Introduced by: Angus S. King Jr. Independent · Maine See on congress.gov
Health Broadcasting, cable, digital technologiesDrug safety, medical device, and laboratory regulationInternet, web applications, social mediaMarketing and advertisingPrescription drugs
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 6, 2025
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Feb 6, 2025
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now February 6, 2025

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Plain-English summary Congressional Research Service

Responsibility in Drug Advertising Act of 2025

This bill prohibits direct-to-consumer advertising of new drugs during the first three years following their approval by the Food and Drug Administration (FDA). Direct-to-consumer advertising includes advertising via social media. 

Upon request from a drug’s sponsor, the FDA may waive the prohibition during the third year following a drug’s approval if it determines that the direct-to-consumer advertising of the drug would have an affirmative value to public health. Conversely, the FDA may prohibit such advertising beyond the three-year period following approval if it determines that the drug has significant adverse health effects based on post-approval studies, adverse event reports, and other appropriate resources. 

The prohibition applies to new drugs approved beginning one year before the bill’s enactment.

 Related & companion bills 1
  • HR 1117 Identical bill Responsibility in Drug Advertising Act of 2025
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 13

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 13 filings →
 Cosponsors 2
All 2 Democratic 2
D
Kaine, Tim
Virginia · Feb 6, 2025
 D
Welch, Peter
Vermont · Feb 6, 2025
Cite this page click to expand
APA
U.S. Congress. (2026). S. 483: Responsibility in Drug Advertising Act of 2025. 119th Congress. Open America. https://openamerica.io/bill/119-S-483/
MLA
"S. 483: Responsibility in Drug Advertising Act of 2025." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-S-483/.
Bluebook (legal)
S. 483, 119th Cong. (2026), https://openamerica.io/bill/119-S-483/.
Markdown link
[S. 483: Responsibility in Drug Advertising Act of 2025](https://openamerica.io/bill/119-S-483/)
Report a problem